Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers
- 15 January 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (2), 447-459
- https://doi.org/10.1158/1078-0432.CCR-20-2657
Abstract
Purpose: Somatic mutations in phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), which encodes the p110a catalytic subunit of PI3K, are found in multiple human cancers. While recurrent mutations in PIK3CA helical, regulatory, and kinase domains lead to constitutive PI3K pathway activation, other mutations remain uncharacterized. To further evaluate their clinical actionability, we designed a basket study for patients with PIK3CA-mutant cancers with the isoform-specific PI3K inhibitor taselisib. Patients and Methods: Patients were enrolled on the basis of local PIK3CA mutation testing into one of 11 histology-specific cohorts and treated with taselisib at 6 or 4 mg daily until progression. Tumor DNA from baseline and progression (when available) was sequenced using a next-generation sequencing panel. Exploratory analyses correlating genomic alterations with treatment outcomes were performed. Results: A total of 166 patients with PIK3CA-mutant cancers were enrolled. The confirmed response rate was 9%. Activity varied by tumor type and mutant allele, with confirmed responses observed in head and neck squamous (15.4%), cervical (10%), and other cancers, plus in tumors containing helical domain mutations. Genomic analyses identified mutations potentially associated with resistance to PI3K inhibition upfront (TP53 and PTEN) and postprogression through reactivation of the PI3K pathway (PTEN, STK11, and PIK3R1). Higher rates of dose modification occurred at higher doses of taselisib, indicating a narrow therapeutic index. Conclusions: Taselisib had limited activity in the tumor types tested and is no longer in development. This genome-driven study improves understanding of the activity, limitations, and resistance mechanisms of using PI3K inhibitors as monotherapy to target PIK3CA-mutant tumors.Other Versions
Funding Information
- Memorial Sloan-Kettering Cancer Center (P30 CA008748)
- F. Hoffmann-La Roche Ltd. Memorial Sloan-Kettering Cancer Center (P30 CA008748)
- NIH (P30 CA008748)
This publication has 42 references indexed in Scilit:
- Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatmentMolecular & Cellular Oncology, 2014
- CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K InhibitorsCancer Cell, 2014
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencingNature Biotechnology, 2013
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroupsNature, 2012
- Tumor Genetic Testing for Patient Selection in Phase I Clinical Trials: The Case of PI3K InhibitorsJournal of Clinical Oncology, 2012
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and ActivityCancer Cell, 2011
- Structure of the LKB1-STRAD-MO25 Complex Reveals an Allosteric Mechanism of Kinase ActivationScience, 2009
- Somatic Mutations in p85α Promote Tumorigenesis through Class IA PI3K ActivationCancer Cell, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009
- The LKB1 tumor suppressor negatively regulates mTOR signalingCancer Cell, 2004